Bibliography
- SUNDEL CL, SOMERS PK, MENG CQ et al: AGI-1067: a multifunctional phenolic antioxidant, lipid modulator, anti-inflammatory and antiatherosclerotic agent. Pharmacol Exp. Ther. (2003) 305:1116–1123.
- TARDIF JC, GREGOIRE J, SCHWARTZ L et al: Effects of AGI-1067 and probucol after percutaneous coronary interventions. Circulation (2003) 107:552–558.
- PARTHASARATHY S, YOUNG SC, WITZTUM JL, PITTMAN RC, STEINBERG D: Probucol inhibits oxidative modification of low density lipoprotein. J. Clin. Invest. (1986) 77:641–644.
- WALLDIUS G, ERIKSON U, OLSSON AG et al: The effect of probucol on femoral atherosclerosis: the Probucol Quantitative Regression Swedish Trial (PQRST). Am. J. Cardiol (1994) 74:875–883.
- JOHANSSON J, OLSSON AG, BERGSTRAND L et al.: Lowering of HDL2b by probucol partly explains the failure of the drug to affect femoral atherosclerosis in subjects with hypercholesterolemia. A Probucol Quantitative Regression Swedish Trial (PQRST) Report. Arterioscler. Thromb. Vasc. Biol. (1995) 15:1049–1056.
- SAWAYAMA Y, SHIMIZI C, MAEDA N et al.: Effects of probucol and pravastatin on common carotid atherosclerosis in patients with asymptomatic hypercholesterolemia. Fukuoka Atherosclerosis Trial (FAST). J. Am. Coll. Cardiol (2002) 39:610–616.
- TARDIF JC, COTE G, LESPERANCE J et al.: Probucol and multivitamins in the prevention of restenosis after coronary angioplasty. Multivitamins and Probucol Study Group. N Engl. J. Med. (1997) 337:365–372.
- YOKOI H, DAIDA H, KUWABARA Y et al.: Effectiveness of an antioxidant in preventing restenosis after percutaneous transluminal coronary angioplasty; the Probucol Angioplasty Restenosis Trial. J. Am. Coll. Cardiol (1997) 30:855–862.
- KLEIN L: QTc-interval prolongation produced by probucol. Arch. Intern. Med. (1981) 141:1102–1103.
- REINOEHL J, FRANKOVICH D, MACHADO C et al: Probucol-associated tachyarrhythmic events and QT prolongation: importance of gender. Am. Heart J. (1996) 131:1184–1191.
- ENGLER MM, ENGLER MB, MALLOY MJ et al: Antioxidant vitamins C and E improve endothelial function in children with hyperlipidemia: Endothelial Assessment of Risk for Lipids in Youth (EARLY) Trial. Circulation (2003) 108:1059–1063.
- TEPEL M, VAN DER GIET M, STATZ M, JANKOWSKI J, ZIDEK W: The antioxidant acetylcysteine reduces cardiovascular events in patients with end-stage renal failure: a randomized, controlled trial. Circulation (2003) 107:992–995.
- TOUSOULIS D, DAVIES G, STEFANADIS C, TOUTOUZAS P, AMBROSE JA: Inflammatory and thrombotic mechanisms in coronary atherosclerosis. Heart (2003) 89:993–997.
- WELT FG, ROGERS C: Inflammation andrestenosis in the stent era. Arterioscler. Throm. Vasc. Biol. (2002) 22:1769–1776.
- SEMB AG, VAN WISSEN S, UELAND T et al.: Raised serum levels of soluble CD40 ligand in patients with familial hypercholesterolemia: downregulatory effects of statin therapy. J. Am. Coll. Cardiol (2003) 41:275–279.
- CHAN AW, BHATT DL, CHEW DP et al: Relation of inflammation and benefit of statins after percutaneous coronary interventions. Circulation (2003) 107:1750–1756.